Vitiligolu Hastalarda Dermatolojik Yaşam Kalite İndeksi Uygulanarak Yaşam Kalitesinin Etkilenme Derecesinin Belirtilmesi
Abstract
Amaç: Vitiligo, dış görünümde göze çarpan renk değişiklikleri nedeniyle kişinin yaşam kalitesini önemli ölçüde etkileyen ve çoğu hastanın kendisini damgalanmış hissetmesine yol açan ciddi bir cilt hastalığıdır. Bu çalışmada vitiligonun hastaların psikolojik ve sosyal yaşantılarına etkilerinin saptanması ve hastaların hastalığı nasıl algıladıklarının anlaşılması amaçlanmaktadır.
Gereç ve Yöntem: Çalışmamız epidemiyolojik bir çalışma olarak tasarlanmıştır. Polikiliniğimize başvuran vitiligolu hastalara ve kontrol gruplarına dermatolojik yaşam kalitesi indeksi uygulandı.
Bulgular: Çalışmamıza 50 vitiligo hastası ve 50 sağlıklı kontrol grubu dahil edildi. Vitiligo hastalarının 26’sı (%52) kadın, 24’ü (%48) erkek’di. Sağlıklı kontrol grubunun 24’ü (%48) kadın, 26’sı (%52) erkek’di. Hastalarımızın yaş ortalamaları ve standart sapmaları 37.2 ± 13.1, sağlıklı kontrol grubunun yaş ortalamaları ve standart sapmaları 34.7 ± 9.2’di. Hastalarımız ve kontrol grubunun yaş ortalamaları istatistiksel olarak uyumlu bulundu (p=0.2). Yaş ve cinsiyet açısından hasta ve kontrol grupları arasında istatistiksel olarak uyum vardı (p<0.05). Ortalama hastalık süresi ve standart sapması 83,9 ± 72,9 ay olarak tespit edildi. Vitiligo klinik tipi olarak en sık görülen alt tip %52 ile fokal vitililigo oldu. Vitiligo ve kontrol gruplarında ortalama DYKİ skoru ve standart sapmaları sırasıyla 5.5 ± 5.0 ve 1.4 ± 1,3 olarak tespit edildi. Hasta grubumuzla sağlıklı kontrol grubu arasında istatistiksel olarak anlamlı bir fark bulundu. (p<0.05)
Sonuç: Bizim çalışmamızdaki bulgular vitiligolu hastalarda yaşam kalitesinin kontrol grubuna göre önemli düzeyde bozulduğunu göstermiştir.
Keywords
References
- 1. Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021;48(3):252-70
- 2. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012;51(10):1206-12
- 3. Ezzedine K, Diallo A, Léauté-Labrèze C, et al. Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo. Br J Dermatol. 2012;167(3):490-95
- 4. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020; 38:621-48
- 5. Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, et al. Immunopathogenesis of vitiligo. Autoimmun Rev 2011;10(12):762-765
- 6. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol. 2000;39(11):801-6
- 7. Acıöz E, Gökdemir G, Köşlü A, Dermatolojide yaşam kalitesi. Turk Arch Dermatol Venereol 2003; 37: 16–23
- 8. Finlay AY, Khan GK. Dermatology life quality index (DLQI)- a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19: 210–216
- 9. Picardo M, Dell'Anna ML, Ezzedine K, et al. Vitiligo. Nat Rev Dis Primers. 2015; 1:15011
- 10. Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863-78
- 11. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473-91
- 12. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-1212.
- 13. Dogra S, Parsad D, Handa S, Kanwar AJ. Late onset vitiligo: a study of 182 patients. Int J Dermatol. 2005;44(3):193-96
- 14. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol. 2003;20(3):207-10
- 15. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148(2):373-74
- 16. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol. 2004; 4:8
- 17. Kent G, al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol. 1996;21(5):330-33
- 18. Rzepecki AK, McLellan BN, Elbuluk N. Beyond Traditional Treatment: The Importance of Psychosocial Therapy in Vitiligo. J Drugs Dermatol. 2018;17(6):688-691
- 19. Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol. 2005;152(6):1165-72
- 20. Al Robaee AA. Assessment of quality of life in Saudi patients with vitiligo in a medical school in Qassim province, Saudi Arabia. Saudi Med J. 2007;28(9):1414-17
- 21. Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol. 2009;161(1):134-39
A determination of the quality of life of patients with vitiligo using the dermatological life quality index
Abstract
Background/aims: Vitiligo is a severe skin disease that significantly affects individuals’ quality of life due to striking color changes in external appearance, and one that causes the majority of patients to feel stigmatized. This study was conducted to determine the effects of vitiligo on patients’ psychological and social lives and to elucidate how they perceive the disease.
Methods: The research was conducted as an epidemiological study. The Dermatological Life Quality Index (DLQI) was applied to patients with vitiligo presenting to our clinic and to a control group.
Results: Fifty patients with vitiligo and 50 healthy individuals were enrolled. The vitiligo group consisted of 26 (52%) women and 24 (48%) men, and the healthy control group of 24 (48%) women and 26 (52%) men. The patients’ mean age was 37.2 ± 13.1 years, and that of the healthy controls 34.7 ± 9.2 years. (p=0.2). No significant age or sex differences were observed between the patient and control groups (p=0.2 and p<0.05, respectively). The mean duration of the disease was 83.9 ± 72.9 months. The most common vitiligo subtype was focal vitiligo, at 52%. The vitiligo and control groups’ mean DLQI scores were 5.5 ± 5.0 and 1.4 ± 1.3, respectively, the difference being statistically significant (p<0.05)
Conclusion: The findings of this study show that the quality of life of the patients with vitiligo was significantly impaired compared to the control group.
Keywords
Ethical Statement
The study was approved by the Atatürk University Medical Faculty ethical committee, Türkiye, under decision no. 53 of session 2, dated 13.03.2009
Supporting Institution
There is no supporter
References
- 1. Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021;48(3):252-70
- 2. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012;51(10):1206-12
- 3. Ezzedine K, Diallo A, Léauté-Labrèze C, et al. Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo. Br J Dermatol. 2012;167(3):490-95
- 4. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020; 38:621-48
- 5. Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, et al. Immunopathogenesis of vitiligo. Autoimmun Rev 2011;10(12):762-765
- 6. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol. 2000;39(11):801-6
- 7. Acıöz E, Gökdemir G, Köşlü A, Dermatolojide yaşam kalitesi. Turk Arch Dermatol Venereol 2003; 37: 16–23
- 8. Finlay AY, Khan GK. Dermatology life quality index (DLQI)- a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19: 210–216
- 9. Picardo M, Dell'Anna ML, Ezzedine K, et al. Vitiligo. Nat Rev Dis Primers. 2015; 1:15011
- 10. Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863-78
- 11. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473-91
- 12. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-1212.
- 13. Dogra S, Parsad D, Handa S, Kanwar AJ. Late onset vitiligo: a study of 182 patients. Int J Dermatol. 2005;44(3):193-96
- 14. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol. 2003;20(3):207-10
- 15. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148(2):373-74
- 16. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol. 2004; 4:8
- 17. Kent G, al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol. 1996;21(5):330-33
- 18. Rzepecki AK, McLellan BN, Elbuluk N. Beyond Traditional Treatment: The Importance of Psychosocial Therapy in Vitiligo. J Drugs Dermatol. 2018;17(6):688-691
- 19. Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol. 2005;152(6):1165-72
- 20. Al Robaee AA. Assessment of quality of life in Saudi patients with vitiligo in a medical school in Qassim province, Saudi Arabia. Saudi Med J. 2007;28(9):1414-17
- 21. Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol. 2009;161(1):134-39
Details
| Primary Language | English |
|---|---|
| Subjects | Dermatology |
| Journal Section | Original Research |
| Authors | |
| Publication Date | March 28, 2024 |
| Submission Date | February 3, 2024 |
| Acceptance Date | March 7, 2024 |
| Published in Issue | Year 2024 Volume: 14 Issue: 2 |
